Covid-19 variants 2024
Pro Research Analysisby 
Searched over 200M research papers
COVID-19 Variants in 2024: Key Strains and Evolution
In 2024, several new COVID-19 variants have emerged, including KP.2, KP.3, and JN.1. These variants have evolved from earlier strains like Delta and Omicron, showing increased ability to evade immune responses, which has led to more breakthrough infections even among vaccinated individuals. The JN.1 variant, an Omicron BA.2.86 lineage, became predominant in the United States by late 2023, replacing earlier XBB lineages that had been circulating widely Kamath2025Link-Gelles2024.
Vaccine Updates and Effectiveness Against 2024 Variants
To address the challenge of new variants, updated COVID-19 vaccines have been developed for the 2023–2024 season. These vaccines, including monovalent formulations targeting the XBB.1.5 subvariant, have been recommended for all individuals aged 6 months and older. The updated vaccines aim to restore waning immunity and provide broader protection against circulating Omicron sublineages, including XBB and JN.1 Kamath2025Regan2023Link-Gelles2024+1 MORE.
Early data show that the updated 2023–2024 monovalent XBB.1.5 vaccines are effective, with about 54% protection against symptomatic infection in adults, even as new variants like JN.1 circulate. The effectiveness remains moderate (49–60%) up to four months after vaccination, indicating ongoing but not complete protection. This supports the need for regular booster doses, especially for high-risk groups Link-Gelles2024Patel2023.
Immune Response and Future Vaccine Strategies
The new XBB.1.5-based vaccines induce strong neutralizing antibody and cellular immune responses against a range of XBB subvariants, including EG.5.1 and XBB.1.16.6. These responses are stronger than those seen with previous bivalent vaccines, supporting the shift to monovalent XBB.1.5 formulations for current and future vaccination campaigns. Future strategies may include annual boosters and the development of mucosal vaccines to further enhance protection Kamath2025Patel2023.
Impact of 2024 Variants on Hospitalizations and High-Risk Groups
Despite updated vaccines, older adults and those with multiple chronic conditions (polypharmacy) remain at higher risk for severe COVID-19 and hospitalization. Most hospitalized patients in 2024 were over 70 years old, had not been previously infected, and many had received multiple vaccine doses. This highlights the importance of prioritizing updated vaccination and early treatment for these vulnerable groups to reduce hospitalizations and deaths .
Neurological Effects of 2024 Variants
Compared to earlier strains, the 2024 COVID-19 variants appear to cause less severe neurological changes, such as those affecting smell and taste. Imaging studies show that the brain microstructure alterations seen with the original 2020 strain are less pronounced with the 2024 variants, suggesting a reduced impact on the nervous system .
Conclusion
In 2024, COVID-19 continues to evolve, with new variants like KP.2, KP.3, and JN.1 challenging existing immunity. Updated vaccines targeting these variants provide moderate protection and are especially important for high-risk populations. Ongoing research, regular vaccine updates, and targeted prevention strategies remain essential to control the impact of COVID-19 as the virus continues to change Kamath2025Regan2023Link-Gelles2024+2 MORE.
Sources and full results
Most relevant research papers on this topic